antisense-oligonucleotides
(2)
Christian Cobaugh
Christian Cobaugh is a molecular biologist turned biotech operator who has spent more than 15 years at the frontier of genetic medicines. In January 2026 he became CEO of Alloy Genetic Medicines, the nucleic-acid division of Alloy Therapeutics, where he leads work on the AntiClastic cyclic nucleic acid platform for ASOs, siRNA, and other RNA therapeutics. He is best known for founding Vernal Biosciences, an mRNA contract manufacturer he built in Colchester, Vermont, on the premise that everyone who needs mRNA should be able to get it. Before Vernal he was the first scientist in the Alexion-Moderna mRNA partnership and held discovery, development, and manufacturing roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics.
Eesha Sharma
Eesha Sharma is the founder and CEO of Lamar Health, a Y Combinator-backed (W21) startup that uses AI to automate the mountain of paperwork standing between patients and high-cost specialty drugs. A genetics PhD from the University of Toronto and former Stanford postdoc, she traded antisense-oligonucleotide research for the unglamorous fight against prior-authorization bureaucracy after watching a family member endure years of misdiagnosis. Lamar Health now serves specialty pharmacies, infusion clinics and hospitals, automating prior auths, document review and EHR connectivity for medications that average roughly $70,000 a year per patient.